BGI Genomics Co Ltd
BGI Genomics Co., Ltd. engages in the provision of genomic sequencing services and proteomic services to academic institutions, pharmaceutical companies, health care providers and other organizations in China and internationally. The company offers DNA sequencing services covering whole genome sequencing, plant/animal whole genome sequencing, exome sequencing, de novo sequencing, and metagenomic … Read more
BGI Genomics Co Ltd - Asset Resilience Ratio
BGI Genomics Co Ltd (300676) has an Asset Resilience Ratio of 3.88% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how BGI Genomics Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down BGI Genomics Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥477.26 Million | 3.88% |
| Total Liquid Assets | CN¥477.26 Million | 3.88% |
Asset Resilience Insights
- Limited Liquidity: BGI Genomics Co Ltd maintains only 3.88% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
BGI Genomics Co Ltd Industry Peers by Asset Resilience Ratio
Compare BGI Genomics Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 14.36% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for BGI Genomics Co Ltd (2015–2024)
The table below shows the annual Asset Resilience Ratio data for BGI Genomics Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.99% | CN¥375.12 Million | CN¥12.54 Billion | -2.54pp |
| 2023-12-31 | 5.54% | CN¥753.58 Million | CN¥13.61 Billion | -3.03pp |
| 2022-12-31 | 8.57% | CN¥1.23 Billion | CN¥14.38 Billion | -5.81pp |
| 2021-12-31 | 14.38% | CN¥2.05 Billion | CN¥14.25 Billion | +6.21pp |
| 2019-12-31 | 8.16% | CN¥482.22 Million | CN¥5.91 Billion | -1.46pp |
| 2018-12-31 | 9.62% | CN¥505.36 Million | CN¥5.25 Billion | -24.90pp |
| 2017-12-31 | 34.52% | CN¥1.76 Billion | CN¥5.11 Billion | -3.51pp |
| 2016-12-31 | 38.03% | CN¥1.61 Billion | CN¥4.23 Billion | -9.52pp |
| 2015-12-31 | 47.56% | CN¥1.86 Billion | CN¥3.91 Billion | -- |